NIRS Monitoring in Premature Infants
Recruiting now
Conditions studied: Hemorrhage, Premature Infants, Newborn, Hydrocephalus
In brief
This study uses frequency domain near-infrared spectroscopy coupled with diffuse correlation spectroscopy (FDNIRS-DCS) technology for monitoring cerebral blood flow (CBF) and cerebral oxygen metabolism (CMRO2) at the bedside for newborns with germinal matrix-intraventricular hemorrhage (GM-IVH) and/or post-hemorrhagic hydrocephalus (PHH) in comparison to newborns with hydrocephalus of a different etiology (VC) and healthy controls (HC). We hypothesize that baseline cerebral metabolic dysfunction is a better biomarker for GM-IVH and PHH severity and response to PHH treatment. This is a Boston Children's Hospital (BCH)-institutional review board(IRB) approved, multi-site study that includes collaboration with Brigham and Women's Hospital (BWH) and Beth Israel Deaconess Medical Center (BIDMC). Pei-Yi Lin receives funding from The National Institute of Health (NIH) to support the study and is the overall principal Investigator (PI) overseeing the study.
Key facts
- Study ID
- NCT02601339
- Run by
- Boston Children's Hospital
- People needed
- 70
- Starts
- 2015-04-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-03-18
Who can join
Age: any, up to 1. Sex: any. Healthy volunteers: accepted.
Where it is running
- Boston Children's Hospital — Boston, Massachusetts, United States (enrolling)
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.